Krystal Biotech, Inc. vs Abbvie Inc.
KRYS vs ABBV — side-by-side comparison from reported financials. KRYS leads 6, ABBV leads 4 of 10 comparable metrics.
Krystal Biotech, Inc.
KRYS · Healthcare
$331.61+1.32%Strained
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | KRYS | ABBV |
|---|---|---|
| Price | $331.61 | $276.43 |
| Market cap | $9.82B | $488B |
| Revenue (TTM) | $440M | $64.4B |
| Revenue growth | +22.6% | +1.8% |
| Net margin | 54.8% | 9.8% |
| Free cash flow | $258M | $18.2B |
| Net cash (debt) | $818M | ($56.2B) |
| 1-year price return | +75.7% | +19.8% |
| P/E | 40.6 | 77.4 |
| P/E vs own history (cheap-side %) | 63% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 19% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 7 of 10 | 9 of 10 |
| Employees | 295 | 57,000 |
Full résumé-style profiles: KRYS CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.